ROY ALLAN ELEVAZO: Open Payments
NPI 1427489483 · LAKEWOOD, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,705 in 87 payments from 10 companies in 2025. Trend: 2023 $2,645 · 2024 $1,482 · 2025 $1,705
Food & beverage: $1,705
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 20 | $399 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 20 | $388 |
| Otsuka America Pharmaceutical, Inc. | 14 | $243 |
| Vanda Pharmaceuticals Inc. | 9 | $174 |
| Axsome Therapeutics, Inc. | 6 | $155 |
| Noven Therapeutics, LLC | 9 | $145 |
| Lundbeck LLC | 3 | $85 |
| Alkermes, Inc. | 3 | $60 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $36 |
| Neos Therapeutics, LP | 1 | $21 |
Products named: VRAYLAR, CAPLYTA, REXULTI, FANAPT, Auvelity, Xelstrym, ARISTADA, TRINTELLIX.
Industry payments across CA — which companies pay providers there.
